Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smaller chest drain may speed recovery after lung cancer surgery

NCT ID NCT07827885

Symptom relief Sponsor: Fondazione Policlinico Universitario Campus Bio-Medico Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers compare two chest drain sizes, 20-Fr and 24-Fr, in people having part of a lung removed for early-stage lung cancer. After surgery, each participant receives one of the two drains to clear fluid and air from the chest. The trial tracks complications such as collapsed lung and fluid buildup, plus pain, air leaks, how long the drain stays in, and hospital stay. The goal is to learn whether a smaller drain helps patients recover with fewer problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
chest drainage tube size (20-Fr versus 24-Fr)
What this could lead to
If a smaller drain works as well, patients could have less pain and shorter hospital stays after lung surgery.
What could go wrong
This is a small, single-center study of 80 people, so the results may not apply to all lung surgery patients. Drain size is only one of many factors that affect recovery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

Jul 2025

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients undergoing pulmonary lobectomy with systematic mediastinal lymphadenectomy for lung cancer using a uniportal video-assisted thoracoscopic approach. * FEV1/FVC \>70%. * Clinical stage up to and including stage IIB according to the eighth or ninth edition of the TNM classification. * No morphological evidence of macrobullous emphysema on computed tomography. Exclusion Criteria: * Neoadjuvant chemoradiotherapy. * Previous ipsilateral pulmonary resection. * FEV1/FVC \<70%. * Clinical stage beyond IIB according to the eighth or ninth edition of the TNM classification. * Macrobullous emphysema on computed tomography. * pregnant and breastfeeding women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

Contacts and locations

Locations

  • Fondazione Policlinico Universitario Campus Bio-Medico

    Rome, Lazio, 00142, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.